gms | German Medical Science

24th Annual Meeting of the German Retina Society

German Retina Society

17.06. - 18.06.2011, Aachen

Article

Send article

Ranibizumab for Branch Retinal Vein Occlusion-Associated Macular Edema Study (RABAMES): 6 month results

Meeting Abstract

Search Medline for

  • Alireza Mirshahi - Universitäts-Augenklinik Mainz
  • A. Pielen - Universitäts-Augenklinik Freiburg
  • N. Feltgen - Universitäts-Augenklinik Göttingen
  • K. Lorenz - Universitäts-Augenklinik Mainz
  • C. Kramann - Universitäts-Augenklinik Mainz
  • L.L. Hansen - Universitäts-Augenklinik Freiburg
  • S.G. Priglinger - AKH Linz
  • L.O. Hattenbach - Klinikum Ludwigshafen

German Retina Society. 24th Annual Conference of the German Retina Society. Aachen, 17.-18.06.2011. Düsseldorf: German Medical Science GMS Publishing House; 2011. Doc11rg46

doi: 10.3205/11rg46, urn:nbn:de:0183-11rg469

This is the English version of the article.
The German version can be found at: http://www.egms.de/de/meetings/rg2011/11rg46.shtml

Published: June 15, 2011

© 2011 Mirshahi et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Background: To compare the efficacy and safety of intravitreal ranibizumab (IVR) to laser photocoagulation and a combination of both in patients with chronic macular edema secondary to branch retinal vein occlusion (BRVO).

Methods: 30 patients were enrolled to this prospective randomized multicenter trial with a macular edema (>3 months) after BRVO. The visual acuity limits were between 20/320 and 20/40. Patients were randomized 1:1:1 to ranibizumab (3 injections) or macular laser photocoagulation or a combination of both. The primary outcome measure was change in best-corrected visual acuity (BCVA) 6 months after baseline. Secondary outcome measures were change in central retinal thickness, number of eyes with ≥5, 10, 15 letter gain in BCVA and <15 letters loss of BCVA, furthermore changes in the fluorescein angiography.

Results: Mean increase in visual acuity was higher in IVR than in laser (LogMAR 0.34 vs. 0.04) and in combination groups (0.34 vs. 0.12). Mean reduction of central retinal thickness was –237 µm in IVR vs. –73 in laser and –98 in the combination groups. No severe complications incl. vitreous hemorrhage, retinal detachment or endophthalmitis occurred.

Conclusions: 6 months results suggest that an initial treatment with 3 x ranibizumab may be superior to laser and combination in improving visual acuity in macular edema secondary to BRVO.